Literature DB >> 30065576

Spironolactone Use to Treat Hypertension: in the Right Patient Groups at the Right Time.

Yusuf Ziya Şener1, Cem Çöteli1, Metin Okşul1.   

Abstract

Entities:  

Year:  2018        PMID： 30065576      PMCID： PMC6066948          DOI： 10.6515/ACS.201807_34(4).20180307A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN： 1011-6842            Impact factor:   2.672


× No keyword cloud information.
  6 in total

Review 1.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  J Am Coll Cardiol       Date:  2017-11-13       Impact factor: 24.094

2.  Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.

Authors:  Halit Diri; Sulbiye Karaburgu; Banu Acmaz; Kursad Unluhizarci; Fatih Tanriverdi; Zuleyha Karaca; Fahrettin Kelestimur
Journal:  Gynecol Endocrinol       Date:  2015-09-15       Impact factor: 2.260

3.  Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia.

Authors:  Toshio Fumoto; Kiyo-Aki Ishii; Masako Ito; Stefan Berger; Günther Schütz; Kyoji Ikeda
Journal:  Biochem Biophys Res Commun       Date:  2014-04-05       Impact factor: 3.575

Review 4.  Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

Authors:  Mitja Lainscak; Francesco Pelliccia; Giuseppe Rosano; Cristiana Vitale; Michele Schiariti; Cesare Greco; Giuseppe Speziale; Carlo Gaudio
Journal:  Int J Cardiol       Date:  2015-05-21       Impact factor: 4.164

Review 5.  A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.

Authors:  Sandra Korol; Fannie Mottet; Sylvie Perreault; William L Baker; Michel White; Simon de Denus
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  Low Dose Spironolactone Monotherapy in the Management of Stage I Essential Hypertension: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Armin Attar; Amir-Abbas Sadeghi; Fatemeh Amirmoezi; Kamran Aghasadeghi
Journal:  Acta Cardiol Sin       Date:  2018-01       Impact factor: 2.672
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.